Semax and selank: overhyped nootropics or genuinely useful peptides?

What did @captainbrootropic actually say?

The creator's core argument is simple: Selank is weak, short-lived, and misunderstood. They claim regular Selank "only lasts from 1.5 to 2 hours" and that it "barely does much" within that window. They also draw a clear line between what Selank is marketed as versus what it actually does, pointing out that "it isn't even made for focus, it just makes you calmer." Semax gets lumped in as equally disappointing, though the creator doesn't break down Semax's mechanism separately. The framing is anti-hype, positioned against TED Talk-style enthusiasm for these compounds. That's a defensible starting point. But the execution is messy, and some of the pharmacological details need unpacking.

Does the science back this up?

On Selank's half-life, the creator is basically right, and that's worth acknowledging. Selank is a synthetic heptapeptide analog of tuftsin, and intranasal bioavailability studies out of Russia suggest a plasma half-life in the range of minutes to a couple of hours. Zozulya et al. (2006, CNS Drug Reviews) documented Selank's anxiolytic profile in clinical trials showing reductions in anxiety without sedation, which maps onto the creator's point that it's calming rather than focusing. The idea that it's a "focus compound" is a TikTok myth, not a pharmacological reality. Semax, on the other hand, has somewhat stronger cognitive signal. Lebedeva et al. (2008, Bulletin of Experimental Biology and Medicine) showed Semax influenced BDNF expression in rat models. Human data is thinner and mostly Russian-language, which limits independent verification.

What did they get wrong (or right)?

They got the Selank mechanism right in spirit: it's primarily anxiolytic, not nootropic in the sharp-focus sense. Credit where it's due. But conflating Semax and Selank as equally ineffective is a stretch. Semax has a distinct mechanism involving ACTH analogs and potential BDNF modulation that Selank doesn't share. Throwing both under the same "ass" umbrella based on personal anecdote is not a scientific comparison. The creator also attributes their Selank experience to a single non-replicating first dose, which is classic placebo territory. Reporting that Selank "did not help me with studying" is valid personal experience, but it's not evidence the compound does nothing. Anecdote dressed as verdict is a pattern worth flagging.

• Correct: Selank's short duration of action is documented
• Correct: Selank is anxiolytic, not a stimulant-style focus enhancer
• Incorrect: Semax and Selank are not pharmacologically equivalent
• Incomplete: No mention of intranasal delivery quality, which affects results significantly

What should you actually know?

If you're considering these peptides for cognitive performance, the honest picture is this: the evidence base is real but limited, mostly Russian-origin, and rarely replicated in Western peer-reviewed journals. Selank has the most consistent human trial data for anxiety reduction, not productivity. Semax has interesting mechanistic data but weak human clinical evidence by FDA standards. Neither compound is approved by the FDA for any indication. Neither has been evaluated for long-term safety in broad populations. Compounded versions available through telehealth vary in purity and concentration, which further complicates any personal report of efficacy or failure. Zozulya et al. (2006) and Semenova et al. (2010, Neurochemical Journal) provide the most cited frameworks, but neither study is a randomized controlled trial by modern standards. The "Limitless pill" framing this creator is pushing back against is genuinely irresponsible marketing. Their skepticism is directionally sound, even if their reasoning is incomplete.